



2013-2014 CCS Position Statement on Familial Hypercholesterolemia Disclosure of Conflict of Interests

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline					
	Consulting fees/ Honoraria	Clinical Trials	Officer, director, or in any other fiduciary role	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Primary Panel						
Jacques Genest	AMGEN, Aegerion, sanofi-aventis	AMGEN, Eli Lilly, Merck	None	None	None	None
Robert Hegele	Abbott, AMGEN, Merck, AstraZeneca, Pfizer, Schering Plough, Tirbute Pharma, Valeant	AMGEN, Eli Lilly, Merck, Acasti Pharma, Aegerion	None	None	None	None
Jean Bergeron	AMGEN, Merck, sanofi-aventis, Valeant Canada	AMGEN, Merck, Novartis, Pfizer, Roche, sanofi-aventis, Amarin, Catabasis, Cortria, ISIS, Regeneron	None	None	None	None
James Brophy	None	None	None	None	None	None
André Carpentier	AstraZeneca, Eli Lilly, Boehringer Ingelheim, Merck, sanofi-aventis, Takeda, UniQure, NovoNordisk	AMGEN, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, sanofi-aventis, Takeda, UniQure, NovoNordisk	None	None	None	Yes
Patrick Couture	AMGEN, AstraZeneca, Merck, Pfizer, Roche	AMGEN, Merck	None	None	None	None
Jean Davignon	AMGEN, Merck, Pfizer, Roche, sanofi-aventis, Valeant	AMGEN, Novartis, sanofi-aventis	Residual Risk Reduction Initiative	None	IRCM	None
Robert Dufour	AMGEN, Merck, Valeant, sanofi-aventis, Regeneron	AMGEN, Novartis, Valeant, sanofi-aventis, Regeneron, Isis, Acasti	None	None	None	None
Jiri Frohlich	AMGEN, AstraZeneca, Pfizer, Servier, sanofi-aventis	AMGEN, Merck, Novartis, Pfizer, sanofi-aventis	None	None	None	None



2013-2014 CCS Position Statement on Familial Hypercholesterolemia

Disclosure of Conflict of Interests

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline					
	Consulting fees/ Honoraria	Clinical Trials	Officer, director, or in any other fiduciary role	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Daniel Gaudet	AMGEN, Novartis, Uniqure, sanofi-aventis, Catabasis, ISIS Pharmaceuticals, Aegerion, Chiesi, Regeneron	AMGEN, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, sanofi-aventis, ISIS Pharmaceuticals, Catabasis, Aegerion, Chiesi, Regeneron, Uniqure	ECOGENE - 21	None	None	None
Milan Gupta	AMGEN, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Pfizer, sanofi-aventis	AMGEN, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb	None	None	None	None
Preetha Krishnamoorthy	Takeda: lecturer on adrenal suppression	None	None	None	None	None
John Mancini	AMGEN, AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, Roche, Srevier, sanofi-aventis, Miraculins	None	President, Vancouver Hospital Medical and Allied Staff	None	None	Miraculins, Inc.
Brian McCrindle	Bristol-Myers Squibb, Eli Lilly, Merck, Janssen, Medpace, Aegerion, Daichii Sankyo	AstraZeneca	None	None	None	None
Paolo Raggi	None	None	None	None	None	None
Isabelle Ruel	None	None	None	None	None	None
Julie St-Pierre	Shire Canada on attention deficit	Novartis on cystic fibrosis	None	None	None	None
Secondary Panel						
David Bewick	AMGEN, AstraZeneca, Bayer, Boehringer Ingelheim,	None	None	None	None	None
Sabyasachi Bose	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed
Francois Bussieres	None	None	None	None	None	None



2013-2014 CCS Position Statement on Familial Hypercholesterolemia

Disclosure of Conflict of Interests

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline					
	Consulting fees/ Honoraria	Clinical Trials	Officer, director, or in any other fiduciary role	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Claude Gagne	None	AMGEN, AstraZeneca, Merck, Novartis, Pfizer, Roche, sanofi-aventis,	None	None	None	None
Sophie Guerin	None	None	None	None	None	None
Pamela Katz	Merck	Pfizer	None	None	None	None
Anne-Marie Laberge	None	None	None	None	None	None
Lawrence A. Leiter	AMGEN, Eli Lilly, Merck, sanofi-aventis	AMGEN, Eli Lilly, Merck, sanofi-aventis	None	None	None	None
Katherine Morrison	None	AstraZeneca	None	None	None	None
Teik Chye Ooi	Abbott Vascular, AMGEN, Aegerion	Novartis, Reata	None	None	None	None
Glen J. Pearson	None	None	None	None	None	None
Tom Ransom	Abbott Vascular, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, Merck, sanofi-aventis, Aegerion, Novo Nordisk, Janssen	AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Medtronic, Merck, Novo Nordisk, Takeda	None	None	None	None
International Advisory Committee						
Fernando Civeira	AMGEN, Merck, sanofi-aventis	AMGEN, Merck, sanofi-aventis	None	None	None	None
Kees Hovingh	AMGEN, AstraZeneca, Novartis, Pfizer, Roche, sanofi-aventis	AMGEN (head of clinical trial unit), AstraZeneca, Eli Lilly, Merck, Novartis, Pfizer, Roche, Takeda, sanofi-aventis, Dezima, Isis, Cerenis	None	None	None	None
Michel Farnier	Abott, AMGEN, Boehringer Ingelheim, Merck, Pfizer, Roche, sanofi-aventis	AMGEN, Merck, sanofi-aventis	None	None	None	None



2013-2014 CCS Position Statement on Familial Hypercholesterolemia

Disclosure of Conflict of Interests

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline					
	Consulting fees/ Honoraria	Clinical Trials	Officer, director, or in any other fiduciary role	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Joshua Knowles	None	None	CMO, The FH Foundation, non-profit	None	None	None
Robert Cramb	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed
Katherine Wilemon	None	None	President, The FH Foundation	None	None	None